Cancer researchers at the University of Bonn have reported significant progress in the treatment of glioblastoma. About one third of all patients suffer from a particular variant of this most common and aggressive brain tumor. ...
Feb 18, 2019
0
273
Scripps Research scientists have discovered a compound that potently and selectively kills the stem-like cells that make glioblastoma brain cancers so deadly.
Mar 08, 2019
0
1517
Researchers at the San Diego branch of the Ludwig Institute for Cancer Research at University of California San Diego, with colleagues around the country, report that inhibiting activity of a specific protein in glioblastomas ...
Feb 28, 2019
0
86
A UCLA-led study suggests that for people with recurrent glioblastoma, administering an immunotherapy drug before surgery is more effective than using the drug afterward.
Feb 11, 2019
0
199
In cancer therapeutics research, microRNAs—tiny strings of nucleotides that get churned out inside cells—have been a source of both excitement and disappointment. While preclinical studies have found that microRNAs play ...
Jan 25, 2019
0
39
(HealthDay)—Neoadjuvant administration of programmed cell death protein 1 (PD-1) blockade seems to enhance local and systemic antitumor immune response in glioblastoma, according to a study published online Feb. 11 in Nature ...
Feb 13, 2019
0
2
Researchers at The University of Texas MD Anderson Cancer Center have discovered an immune regulator that appears to dictate glioblastoma (GBM) progression by shutting down immune surveillance, indicating a potential new ...
Jan 25, 2019
0
37
Columbia researchers have learned why some glioblastomas—the most common type of brain cancer—respond to immunotherapy. The findings could help identify patients who are most likely to benefit from treatment with immunotherapy ...
Feb 15, 2019
0
5
For decades, scientists have recognized that more males get cancer and die of the disease than females. This is true for many types of cancer, including the deadly brain tumor glioblastoma. Now, a team of researchers led ...
Jan 02, 2019
0
462
A study led by investigators from Massachusetts General Hospital (MGH) and the University of Cyprus reveals details of a way the dangerous brain tumors called glioblastomas resist the effects of antiangiogenic drugs designed ...
Jan 30, 2019
0
29
Hope for treating the kind of brain cancer that took the life of U.S. Sen. John McCain lies with a compound, identified by researchers at UWM and the Medical College of Wisconsin, that slows the growth of this aggressive ...
Jan 21, 2019
0
6
A Massachusetts General Hospital (MGH)-led research team has demonstrated, for the first time, how solid stress—the physical forces exerted by the solid components of a tumor—impacts the tissue surrounding brain tumors ...
Jan 07, 2019
0
103
Around a glioblastoma, a very aggressive brain tumor, cells of the human immune system help the tumor instead of attacking it. To explore the interaction of these cells, scientists of the University of Twente have created ...
Feb 08, 2019
0
2
A biomedical tool that tricks aggressive brain tumors such as glioblastoma into migrating into an external container rather than throughout the brain has been designated a "Breakthrough Device" by the U.S. Food and Drug Administration ...
Feb 06, 2019
0
4875
In southwest London, on the edge of Bushy Park, is a building whose occupants are responsible for measurements. Precise measurements, to be precise. The building is the gatekeeper of time, the resting place of the kilogram, ...
Feb 15, 2019
0
1
Glioblastoma multiforme (GBM) is the most common and most aggressive malignant primary brain tumor in humans, involving glial cells and accounting for 52% of all functional tissue brain tumor cases and 20% of all intracranial tumors. Despite being the most prevalent form of primary brain tumor, GBMs occur in only 2–3 cases per 100,000 people in Europe and North America. According to the WHO classification of the tumors of the central nervous system, the standard name for this brain tumor is "glioblastoma"; it presents two variants: giant cell glioblastoma and gliosarcoma. Glioblastomas are also an important brain tumor in canines, and research continues to use this as a model for developing treatments in humans.
Treatment can involve chemotherapy, radiation, radiosurgery, corticosteroids, antiangiogenic therapy, surgery and experimental approaches such as gene transfer.
With the exception of the brainstem gliomas, glioblastoma has the worst prognosis of any central nervous system (CNS) malignancy, despite multimodality treatment consisting of open craniotomy with surgical resection of as much of the tumor as possible, followed by concurrent or sequential chemoradiotherapy, antiangiogenic therapy with bevacizumab, gamma knife radiosurgery, and symptomatic management with corticosteroids. Prognosis is poor, with a median survival time of approximately 14 months.
This text uses material from Wikipedia licensed under CC BY-SA
